AstraZeneca Signs AI Drug Discovery Deal With Insitro Worth Up to $1.5 Billion

AstraZeneca and the AI-focused biotech company insitro announced a research collaboration on October 15, 2026, aimed at discovering new treatments for MASH, a form of liver disease, and for cardiomyopathies, a group of heart muscle conditions.

Under the deal, insitro will use its Virtual Human platform, which combines lab-grown cell models with machine learning, to identify the underlying biology driving each disease. The company will then advance targets nominated by AstraZeneca from early discovery through to development candidates.

AstraZeneca will take over from there, leading all clinical development, regulatory submissions and commercialization if any candidates reach that stage. No drug candidates have been named yet, and any targets identified through the AI analysis would still need to pass through preclinical and clinical testing before their value can be assessed.

Financially, insitro is set to receive $40 million upfront, with the potential to earn roughly $1.46 billion more in development and commercial milestone payments, plus royalties on any resulting sales. Some reports put the deal's total potential value as high as $1.86 billion, citing Bloomberg, while other outlets cite the roughly $1.5 billion figure drawn from the disclosed upfront and milestone amounts.

The partnership extends AstraZeneca's push into MASH, a liver disease market some analysts expect to be worth more than $20 billion by the early 2030s. The company had previously dropped an earlier MASH drug candidate after disappointing results in a mid-stage clinical trial.

The deal is the latest example of large pharmaceutical companies turning to AI-driven biotech firms to speed up the early, often slowest stage of drug discovery, rather than building that capability entirely in-house.